Cardiff Oncology

Yahoo Finance • 20 days ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical dat... Full story

Yahoo Finance • 20 days ago

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company mana... Full story

Yahoo Finance • last month

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company mana... Full story

Yahoo Finance • 2 months ago

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight

DelveInsight Business Research LLP The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Mer... Full story

Yahoo Finance • 2 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004... Full story

Yahoo Finance • 2 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company mana... Full story

Yahoo Finance • 2 months ago

Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates

(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:... Full story

Yahoo Finance • 4 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company mana... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright lowers Cardiff Oncology stock price target on trial data

Investing.com - H.C. Wainwright has reduced its price target on Cardiff Oncology (NASDAQ:CRDF) to $10.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $2.57, the clinical-stage biotech company has a market c... Full story

Yahoo Finance • 5 months ago

These stocks are moving in today's pre-market session

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] GAINERS TICKER CHANGE COMMENT REPL [htt... Full story

Yahoo Finance • 5 months ago

What's going on in today's after hours session

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/... Full story

Yahoo Finance • 5 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm –... Full story

Yahoo Finance • 6 months ago

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions... Full story

Yahoo Finance • 6 months ago

Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann

Investing.com - Ladenburg Thalmann initiated coverage on Cardiff Oncology (NASDAQ:CRDF), currently trading at $3.65 with a market cap of $243 million, with a Buy rating and a $19.00 price target on Tuesday. According to InvestingPro data,... Full story

Yahoo Finance • 6 months ago

Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns

Investing.com - Jefferies initiated coverage on Cardiff Oncology (NASDAQ:CRDF) with a Hold rating and a $3.50 price target on Monday. The research firm cited promising early data for Cardiff’s onvansertib, a PLK1 inhibitor, in first-line... Full story

Yahoo Finance • 6 months ago

Cardiff Oncology to share CRDF-004 trial data on July 29

The company said last night, “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantiv... Full story

Yahoo Finance • 6 months ago

Cardiff selloff brings attractive entry point, says H.C. Wainwright

H.C. Wainwright says the “market overreaction” in shares of Cardiff Oncology (CRDF) “provides an attractive stock price entry point.” Cardiff announced that it will now share updated clinical data from the CRDF-004 trial on July 29, as opp... Full story

Yahoo Finance • 6 months ago

Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer

SAN DIEGO - Cardiff Oncology, Inc. (NASDAQ:CRDF) has appointed Roger Sidhu, MD, as Chief Medical Officer, replacing Dr. Fairooz Kabbinavar who will remain with the company in an advisory role, according to a press release statement. The cl... Full story

Yahoo Finance • 6 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call o... Full story

Yahoo Finance • 7 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclit... Full story